Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty
(2004) In Acta Pædiatrica 93(11). p.1456-1462- Abstract
- Background: Girls adopted from developing countries often have early or precocious puberty, requiring treatment with gonadotrophin-releasing hormone (GnRH) analogues. During such treatment, decreased growth velocity is frequent. Aim: To study whether the addition of growth hormone (GH) to GnRH analogue treatment improves final height in girls with early or precocious puberty. Methods: Forty-six girls with early or precocious puberty (age less than or equal to9.5 y) adopted from developing countries were randomized for treatment for 2-4 y with GnRH analogue, or with a combination of GH and GnRH analogue. Results: During treatment, the mean growth velocity in the GH/GnRH analogue group was significantly higher compared to the control group.... (More)
- Background: Girls adopted from developing countries often have early or precocious puberty, requiring treatment with gonadotrophin-releasing hormone (GnRH) analogues. During such treatment, decreased growth velocity is frequent. Aim: To study whether the addition of growth hormone (GH) to GnRH analogue treatment improves final height in girls with early or precocious puberty. Methods: Forty-six girls with early or precocious puberty (age less than or equal to9.5 y) adopted from developing countries were randomized for treatment for 2-4 y with GnRH analogue, or with a combination of GH and GnRH analogue. Results: During treatment, the mean growth velocity in the GH/GnRH analogue group was significantly higher compared to the control group. Combined GH/GnRH analogue treatment resulted in a higher final height: 158.9 cm compared to 155.8 cm in the GnRH analogue-treated group. Three out of 24 girls (13%) in the combined group and nine of the 22 girls (41%) treated with GnRH analogue alone attained a final height below -2 standard deviation scores (SDS). Conclusion: The difference between the two groups is statistically significant, and possibly of clinical importance. A future challenge is to identify a subgroup with clinically significant advantage of GH addition to GnRH analogue treatment. Being very short on arrival in Sweden and being short and young at start of treatment are possible indicators. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/265496
- author
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- clinical trial, controlled, girls, growth hormone, GnRH analogue, puberty, precocious
- in
- Acta Pædiatrica
- volume
- 93
- issue
- 11
- pages
- 1456 - 1462
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:15513572
- wos:000224349500012
- scopus:7644230926
- ISSN
- 1651-2227
- DOI
- 10.1111/j.1651-2227.2004.tb02629.x
- language
- English
- LU publication?
- yes
- id
- 3f9406f6-fa7e-488a-af7c-80f22d03c563 (old id 265496)
- date added to LUP
- 2016-04-01 15:17:52
- date last changed
- 2022-03-14 17:33:28
@article{3f9406f6-fa7e-488a-af7c-80f22d03c563, abstract = {{Background: Girls adopted from developing countries often have early or precocious puberty, requiring treatment with gonadotrophin-releasing hormone (GnRH) analogues. During such treatment, decreased growth velocity is frequent. Aim: To study whether the addition of growth hormone (GH) to GnRH analogue treatment improves final height in girls with early or precocious puberty. Methods: Forty-six girls with early or precocious puberty (age less than or equal to9.5 y) adopted from developing countries were randomized for treatment for 2-4 y with GnRH analogue, or with a combination of GH and GnRH analogue. Results: During treatment, the mean growth velocity in the GH/GnRH analogue group was significantly higher compared to the control group. Combined GH/GnRH analogue treatment resulted in a higher final height: 158.9 cm compared to 155.8 cm in the GnRH analogue-treated group. Three out of 24 girls (13%) in the combined group and nine of the 22 girls (41%) treated with GnRH analogue alone attained a final height below -2 standard deviation scores (SDS). Conclusion: The difference between the two groups is statistically significant, and possibly of clinical importance. A future challenge is to identify a subgroup with clinically significant advantage of GH addition to GnRH analogue treatment. Being very short on arrival in Sweden and being short and young at start of treatment are possible indicators.}}, author = {{Tuvemo, T and Jonsson, B and Gustafsson, J and Albertsson-Wikland, K and Aronson, AS and Hager, A and Ivarson, S and Kristrom, B and Marcus, C and Nilsson, Karl-Olof and Westgren, U and Westphal, O and Aman, J and Proos, LA}}, issn = {{1651-2227}}, keywords = {{clinical trial; controlled; girls; growth hormone; GnRH analogue; puberty; precocious}}, language = {{eng}}, number = {{11}}, pages = {{1456--1462}}, publisher = {{Wiley-Blackwell}}, series = {{Acta Pædiatrica}}, title = {{Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty}}, url = {{http://dx.doi.org/10.1111/j.1651-2227.2004.tb02629.x}}, doi = {{10.1111/j.1651-2227.2004.tb02629.x}}, volume = {{93}}, year = {{2004}}, }